Israel-based, biopharmaceutical company Kitov Pharmaceuticals has reported positive data following the successful completion of its Phase III trial of combination drug KIT-302 to improve renal function.

KIT-302 is a combination of the US Food and Drug Administration (FDA) approved drug celecoxib (Celebrex), which treats pain triggered by osteoarthritis, and another FDA-approved drug amlodipine besylate, which treats hypertension.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The double-blind, placebo-controlled Phase III trial was intended to quantify the decrease of hypertension in patients administered with KIT-302.

The trial included four groups of 26 to 49 patients each, with a total of 152 patients and was performed in the UK. Each patient was treated over duration of two weeks.

"The company noted that the final results have exhibited a greater rate of reduction in daytime systolic blood pressure after being treated with KIT-302."

Group I was treated with KIT-302, group II was only treated with amlodipine besylate, while group III was only treated with celecoxib and group IV was treated with a double placebo.

See Also:

The trial was primarily focused on demonstrating the capability of the combination of the two KIT-302 components, administered to Group One, in reducing daytime systolic blood pressure by at least 50% of the reduction in blood pressure achieved within patients in Group Two, who were only treated with amlodipine besylate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company noted that the final results have exhibited a greater rate of reduction in daytime systolic blood pressure after being treated with KIT-302.

Furthermore, analysis of the Phase III clinical trial data has also demonstrated the ability of the combination drug KIT-302 in reducing plasma levels of creatinine, thereby improving the renal function, which is affected by nonsteroidal anti-inflammatory drugs (NSAIDs).

Kitov chief medical officer Dr Paul Waymack said: "We are very pleased with the outcome of the renal function analysis.

"We believe it demonstrates that, in addition to addressing hypertension side effects caused by celecoxib, KIT-302 also addresses fluid retention resulting from amlodipine: a known side effect caused by calcium channel blockers."

According to Kitov CEO Isaac Israel, the company is planning to conduct another clinical trial for a scientific validation of the renal benefits rendered by KIT-302, along with submitting the new drug application (NDA) at the end of this year.